Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result
This followed announcements that its drug candidate—gedatolisib, in combination with two other drugs (called the triplet)—showed a marked 76 percent reduction in the disease progression of enrolled...




